Beam Therapeutics Inc.BEAM

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · beamtx.com

Beam Therapeutics is a biotechnology company committed to establishing a leading, fully integrated platform for precision genetic medicines, with integrated gene editing, delivery and internal manufacturing capabilities anchored by its proprietary base editing technology. Base editing is designed to enable precise, predictable and efficient single base changes at targeted genomic sequences without double-stranded DNA breaks, supporting a diversified portfolio of base editing programs.

Key ratios

FCF / Sales

-238.9%TTM

2025 -257.7%2024 -560.8%2023 -48.4%

Net margin

-55.5%TTM

2025 -57.2%2023 -35.1%

ROA

-17.0%TTM

2025 -18.6%2024 -20.3%2023 -7.9%

ROE

-8.2%TTM

2025 -8.1%2024 -43.9%2023 -15.5%

Revenue growth

158.9%TTM

2025 120.0%2024 -83.2%2023 520.0%

Recent news

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 2026-09-08 · GlobeNewswire Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences 2026-08-31 · GlobeNewswire

Track BEAM in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer